Back to results
US 2022/0031726 A1Published application
Novel combination treatment for acute myeloid leukemia (aml)
AssigneeHoffmann-La Roche Inc.
InventorsBrian Higgins, Kathryn E. Packman, Gwen Nichols
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction; and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer, particularly AML.
Claims20
A pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction;
- and b) as a second component cytarabine;
- as a combined preparation for the sequential or simultaneous use in the treatment of cancer.
(canceled)
(canceled)
Dependencies are inferred from the claim text.